News Amgen Inc.

Stocks

AMGN

US0311621009

Pharmaceuticals

Real-time Estimate Cboe BZX 15:30:11 2026-08-21 EDT			5-day change	1st Jan Change
437.60 ^USD	+1.48%		+5.58%	+33.94%

01:34pm	FTC Challenges Amgen's Patent Play in Enbrel Antitrust Case	DJ
08-20	Piper Sandler Adjusts Price Target on Amgen to $457 From $427, Maintains Overweight Rating	MT

All News

Mentions Relevance

01:34pm	FTC Challenges Amgen's Patent Play in Enbrel Antitrust Case	DJ
08-20	Piper Sandler Adjusts Price Target on Amgen to $457 From $427, Maintains Overweight Rating	MT
08-19	Argus Research Adjusts Amgen Price Target to $460 From $375, Maintains Buy Rating	MT
08-19	Morgan Stanley Adjusts Price Target on Amgen to $362 From $351, Keeps Equalweight Rating	MT
08-18	Mizuho Adjusts Price Target on Amgen to $352 From $303, Maintains Neutral Rating	MT
08-18	Cantor Fitzgerald Adjusts Price Target on Amgen to $400 From $350, Maintains Neutral Rating	MT
08-17	Mizuho Securities Adjusts Amgen Price Target to $352 From $303	MT
08-14	Amgen Insider Sold Shares Worth $1,346,499, According to a Recent SEC Filing	MT
08-13	Daiwa Securities Adjusts Price Target on Amgen to $430 From $390, Keeps Outperform Rating	MT
08-13	Barclays Adjusts Price Target on Amgen to $380 From $360, Maintains Equalweight Rating	MT
08-10	HSBC Adjusts Price Target on Amgen to $445 From $425, Keeps Buy Rating	MT
08-10	Amgen Insider Sold Shares Worth $1,194,416, According to a Recent SEC Filing	MT
08-10	Amgen Insider Sold Shares Worth $1,565,898, According to a Recent SEC Filing	MT
08-07	Citigroup Adjusts Price Target on Amgen to $405 From $345, Maintains Neutral Rating	MT
08-06	Rothschild & Co Redburn Adjusts Amgen Price Target to $235 From $220, Maintains Sell Rating	MT
08-05	Dow closes at record on Mideast optimism; SpaceX, AMD drag Nasdaq	RE
08-05	Bernstein Adjusts Price Target on Amgen to $345 From $335, Maintains Market Perform Rating	MT
08-05	UBS Adjusts Price Target on Amgen to $440 From $420, Maintains Buy Rating	MT
08-05	JPMorgan Adjusts Price Target on Amgen to $350 From $300, Maintains Neutral Rating	MT
08-05	Wells Fargo Adjusts Price Target on Amgen to $400 From $390, Maintains Equalweight Rating	MT
08-05	Leerink Partners Adjusts Price Target on Amgen to $395 From $355, Maintains Market Perform Rating	MT
08-05	TD Cowen Adjusts Price Target on Amgen to $452 From $420, Maintains Buy Rating	MT
08-05	Goldman Sachs Adjusts Price Target on Amgen to $450 From $427, Maintains Buy Rating	MT
08-05	BMO Capital Adjusts Price Target on Amgen to $450 From $400, Maintains Outperform Rating	MT
08-05	Scotiabank Adjusts Price Target on Amgen to $450 From $385, Maintains Sector Outperform Rating	MT